Effect of intravenous ketorolac and magnesium sulfate versus intravenous ketorolac and placebo on femur intertrochanteric fracture pain alleviation

Effect of intravenous ketorolac and magnesium sulfate versus intravenous ketorolac and placebo on femur intertrochanteric fracture pain alleviation: a double-blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N373

Enrollment

Registered

2020-12-17

Start date

2020-07-05

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain. Acute pain due to trauma

Interventions

Intervention 1: Intervention group: Intravenous infusion of ketorolac 30 mg plus magnesium sulfate 15 mg/kg in 100 ml normal saline within 20 minutes. Intervention 2: Control group: Intravenous infusi

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 80 years, Femur intertrochanteric fracture,

Exclusion criteria

Exclusion criteria: Open fracture, Unstable vital signs, Neurovascular trauma, Recent use of calcium, Addiction, Renal or liver diseases, Peptic ulcer, Coagulopathy disorders Cardiac arrhythmia

Design outcomes

Primary

Measure	Time frame
Pain severity. Timepoint: Before the intervention and 20, 40, and 60 minutes after the intervention. Method of measurement: By Visual Analog Scale (VAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Arab Ghahestani

Hamedan University of Medical Sciences

abbasumsha@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026